Biosynex

Research Biosynex (ALBIO) on Bullrun: market cap EUR 16.77M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is EUR 16.77M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025EUR 95.19M-EUR 58.22M-EUR 8.57M55.0%-4.03EUR 8.46MEUR 61.65MEUR 34.95M
FY2024EUR 101.17M-EUR 43.33M-EUR 14.96M56.8%-3.33EUR 4.69MEUR 62.46MEUR 80.58M
FY2023EUR 92.98M-EUR 36.95M-EUR 49.20M52.8%-2.85EUR 20.17MEUR 65.96MEUR 124.48M
FY2022EUR 196.59MEUR 15.66M-EUR 32.83M52.1%1.26EUR 87.17MEUR 52.08MEUR 162.53M
FY2021EUR 382.53MEUR 104.00MEUR 90.82M54.0%8.27EUR 132.03MEUR 35.16MEUR 167.81M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-27EUR 16.77Mn/an/a0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 EUR.

YearDividends/share
FY20221.65 EUR
FY20210.17 EUR

About Biosynex

Biosynex SA designs, manufactures, and distributes rapid diagnostic tests to patients and healthcare professionals in France and internationally. The company develops and markets IVDs in the form of RDTs and TRODs, immunoblot, molecular biology, and POC for screening, diagnosis, and prevention.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Biosynex's market cap?

Biosynex's market capitalization is EUR 16.77M.

What does Biosynex do?

Biosynex SA designs, manufactures, and distributes rapid diagnostic tests to patients and healthcare professionals in France and internationally. The company develops and markets IVDs in the form of RDTs and TRODs, immunoblot, molecular biology, and POC for screening, diagnosis, and prevention. It also provides thermometers, tensiometers, oximetry, hearing protection products, oral and dental hygiene products, self-tests, thermal pads, inhalation chambers, and thermotherapy products, as well as anti-mosquito bracelets and waterproof, moisturizing, and sensitive skin spray.